Second Regular Session Seventy-fourth General Assembly STATE OF COLORADO

REVISED

This Version Includes All Amendments Adopted on Second Reading in the Second House

LLS NO. 24-1151.01 Richard Sweetman x4333

SENATE BILL 24-203

SENATE SPONSORSHIP

Ginal and Kirkmeyer, Michaelson Jenet, Smallwood, Will, Zenzinger, Buckner, Cutter, Lundeen, Mullica, Priola, Simpson

HOUSE SPONSORSHIP

Hartsook and Ortiz, Bird, Bradfield, Brown, deGruy Kennedy, Pugliese, Young

Senate Committees State, Veterans, & Military Affairs **House Committees** Health & Human Services

A BILL FOR AN ACT

101	CONCERNING REQUIRING THE COLORADO PRESCRIPTION DRUG
102	AFFORDABILITY REVIEW BOARD TO CONSIDER INPUT FROM THE
103	COLORADO RARE DISEASE ADVISORY COUNCIL UNDER CERTAIN
104	CIRCUMSTANCES.

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at http://leg.colorado.gov.)

Current law requires the Colorado prescription drug affordability review board (board) to take certain measures in determining whether to conduct an affordability review for an identified prescription drug. The





bill requires the board, in making such a determination, to consider whether the drug has an approved orphan drug designation for one or more rare diseases and no other indications and, if so, to consider input from consumers and the Colorado rare disease advisory council (council).

Current law requires the board, in performing an affordability review, to consider certain information. The bill requires the board to consider input from the council.

1	Be it enacted by the General Assembly of the State of Colorado:
2	SECTION 1. In Colorado Revised Statutes, 10-16-1406, amend
3	(2)(c), (2)(d), and (4)(h); and add (2)(e) as follows:
4	10-16-1406. Colorado prescription drug affordability review
5	board - affordability reviews of prescription drugs - repeal. (2) After
6	identifying prescription drugs as described in subsection (1) of this
7	section, the board shall determine whether to conduct an affordability
8	review for each identified prescription drug by:
9	(c) Seeking and considering input from the advisory council about
10	the prescription drug; and
11	(d) Considering the average patient's out-of-pocket cost for the
12	prescription drug; AND
13	(e) CONSIDERING WHETHER THE DRUG HAS AN APPROVED ORPHAN
14	DRUG DESIGNATION FOR ONE OR MORE RARE DISEASES AND NO OTHER
15	INDICATIONS AND, IF SO, CONSIDERING INPUT FROM CONSUMERS AND THE
16	COLORADO RARE DISEASE ADVISORY COUNCIL CREATED IN SECTION
17	25-1-1503.
18	(4) In performing an affordability review, to the extent
19	practicable, the board shall consider:
20	(h) Input from:
21	(I) Patients and caregivers affected by the condition or disease that
22	is treated by the prescription drug that is under review by the board; and

203

1	(II) Individuals who possess scientific or medical training with
2	respect to a condition or disease treated by the prescription drug that is
3	under review by the board; AND
4	(III) THE RARE DISEASE ADVISORY COUNCIL CREATED IN SECTION
5	25-1-1503.
6	SECTION 2. In Colorado Revised Statutes, 25-1-1505, amend
7	(3)(d) and (3)(e); and add (3)(f) as follows:
8	25-1-1505. Activities carried out by the council - duties. (3) In
9	addition to any other council activities, the council may:
10	(d) Publicize its findings and recommendations concerning the
11	needs of individuals with rare diseases living in Colorado and advocate
12	on behalf of the council for its recommended actions; and
13	(e) Seek, accept, and expend gifts, grants, and donations for
14	purposes of carrying out the duties of the council; AND
15	(f) OFFER INPUT TO THE COLORADO PRESCRIPTION DRUG
16	AFFORDABILITY REVIEW BOARD, AS DESCRIBED IN SECTION 10-16-1406
17	(2)(e) AND $(4)(h)(III)$.
18	SECTION 3. Act subject to petition - effective date. This act
19	takes effect at 12:01 a.m. on the day following the expiration of the
20	ninety-day period after final adjournment of the general assembly; except
21	that, if a referendum petition is filed pursuant to section 1 (3) of article V
22	of the state constitution against this act or an item, section, or part of this
23	act within such period, then the act, item, section, or part will not take
24	effect unless approved by the people at the general election to be held in
25	November 2024 and, in such case, will take effect on the date of the
26	official declaration of the vote thereon by the governor.